Context: Growth hormone deficiency (GHD) in children may be associated with early cardiovascular risk factors and alterations in left ventricular (LV) structure and function; data on cardiopulmonary functional capacity are lacking.
I
t has been well established that growth hormone (GH) regulates intermediate metabolism, body composition and cardiovascular (CV) health, thus influencing physical performance, general well-being, and quality of life (1) .
In adult-onset GH deficiency (GHD), fat mass (FM) is increased and lean body mass (LBM) is reduced causing diminished muscle strength and physical fitness (2) . There is usually an increase in muscle mass in response to GH, but whether this change results in increased strength is still debated. However, overall data suggest that GH treatment significantly improves aerobic exercise capacity and physical performance (3, 4) . This is relevant even in childhood because, in addition to promoting linear growth, GH also exerts beneficial effects on early risk factors involved in the development of CV morbidity and mortality (5) . Several studies have documented that untreated GHD during childhood may be associated to subtle alterations in body composition (6, 7) , lipid profile (8) (9) (10) , and cardiac performance (11, 12) . In particular, untreated GHD children may display increased visceral adiposity expressed as both waist-tohip ratio (WHR) and waist-to-height ratio (WHtR) (7, 8) , increased FM, and decreased LBM at dual-energy x-ray absorptiometry (DXA) (6) , which are improved by GH replacement therapy. Moreover, untreated GHD children exhibit reduced cardiac size and subclinical alterations in left ventricular (LV) systolic contractility, documented by higher wall stress, impaired mean velocity of circumferential fiber-shortening and stress-shortening index, with a normal global systolic function expressed by LV fractional shortening (LVFS) and LV ejection fraction (LVEF) (13) . All these abnormalities are reversible after GH replacement therapy (13) . However, the relationship between such metabolic and cardiac abnormalities and cardiopulmonary functional capacity in children with GHD is unknown.
Right ventricle (RV) function is of essential clinical and prognostic importance in a variety of lung diseases, pulmonary hypertension (14) , and acquired and congenital heart disease (15) . There are no data available about RV function and remodeling in GHD children with and without GH replacement therapy.
We designed this observational, case-control, prospective study to evaluate the effects of GH deficiency and 1-year GH replacement therapy on cardiopulmonary function, cardiac performance, and body composition in children.
Materials and Methods

Patients and controls
Twenty-one children with untreated isolated GHD (17 boys and four girls) aged 11.3 6 0.8 years (range = 10.0 to 12.5 years) have been enrolled in the study. Diagnosis of GHD was made according to clinical and auxological criteria associated with insufficient GH response (peak GH ,8 mg/L) after two stimulation tests (mean GH peak 5.9 6 0.82 mg/L after arginine and 5.4 6 1.37 mg/L after glucagon) (16) . Magnetic resonance imaging documented pituitary hypoplasia in four patients, empty sella in four, and pars intermedia cyst in one.
None of the patients had been previously treated with GH. All the patients were commenced on GH at a mean dose of 30 mg/kg/d.
To assess the physical activity (PA) level, a modified version of the International Physical Activity Questionnaire was administered to the all subjects' parents (17) . The questionnaire comprises a set of four domains: (1) school-related PA, (2) transportation, (3) housework, and (4) leisure time. For each domain, the number of days per week and of PA periods per day (.10 minutes of walking or moderate or vigorous activity) were recorded. Based on these variables, three categories of PA level have been established namely high, moderate, and low intensity (17) . A high level of PA was defined as vigorous activity in more than 3 days per week, accounting for at least 1500 metabolic equivalent minutes per week; a moderate level of PA was defined as 3 days or more of vigorous PA lasting at least 20 minutes or 5 or more days of moderate activity and/or walking at least 30 minutes per day; and a low level of PA was defined as no activity or some activity reported, but not enough to meet criteria for a moderate level of PA.
Twenty-one healthy subjects matched for sex, pubertal status, body mass index (BMI), and PA level participated into the study as controls. These subjects were referred to our unit for short stature and were diagnosed, following appropriate assessment, as having familial short stature or constitutional delay of growth and puberty.
All subjects were prepubertal at study entry. During the study, a comparable proportion of GHD subjects (two females and two males) and controls (three females and two males) entered puberty. Previous or current CV, respiratory, or endocrine diseases were exclusion criteria for entering the study in both GHD patients and controls.
The study was approved by our Institutional Ethical Committee. Informed parental consent for participation into the study was obtained for patients and controls.
Study design
This was a 1-year prospective case-control study. At study entry, all subjects underwent careful clinical examination including anthropometric measures, heart rate (HR), systolic blood pressure (BP), diastolic BP, and assessment of serum insulinlike growth factor (IGF)-1 concentrations. Echocardiography and cardiopulmonary exercise testing were performed to evaluate cardiopulmonary function. DXA was performed to evaluate the relationship between body composition and physical performance.The evaluation of all the parameters was then repeated after 1 year of GH treatment in GHD, whereas in controls was repeated after a 1-year follow-up, with the exception of DXA, because of ethical reasons.
Anthropometric measurements
Height was measured in the upright position using a Herpenden stadiometer (Holtain, Ltd., Crymmyth, UK) and was expressed in standard deviation score (SDS) according to Italian reference standards (18) . BMI was calculated by dividing weight in kilograms by the square of height in meters and then expressed as SDS according to Italian reference standards (18) . Waist circumference was measured by the same operator in the standing position with a nonelastic tape placed at the midpoint between the lower rib margin and the iliac crest. Hip circumference was measured at the level of widest portion of trochanters. All measurements were expressed in centimeters to the nearest 0.1 cm. WHR and WHtR were used to evaluate visceral adiposity. BP was registered as the mean value of three measurements after 10 minutes in a seated position.
Serum assay
Serum GH and IGF-I concentrations were determined by a solid-phase, enzyme-labeled chemiluminescent immunometric assay (Immulite 2000 Siemens Healthcare Diagnostics Inc., New York, NY). IGF-1 concentrations were expressed as SDS according to the normative data provided by the manufacturer.
DXA
In all subjects, body composition was evaluated by DXA using a Hologic QDR 1000 densitometer (Hologic, Waltham, MA). Daily calibrations of the densitometer performed with a phantom during a 1-year period had provided a coefficient of variation of 0.56%. All examinations were carried out in the continuous presence of trained technicians. LBM and FM were measured in all patients and expressed both in absolute values and percentage of body composition.
Echocardiography
Transthoracic echocardiography was performed in conscious patients in supine position to evaluate subcostal, parasternal, and apical view. If required the apical view was obtained in left lateral decubitus position. It was recorded by Sequoia C256 system equipped with 7V3c (3 to 7 MHz) and 3V2c (2 to 3 MHz) probes.
To evaluate the LV function and structure, we measured the following: (1) LV end diastolic diameter (LVEDD) and LV end systolic diameter (LVESD), by M-mode parasternal short axis view; (2) LV mass (LVM), by M-mode parasternal short axis view (measuring septal, IVST, and posterior wall thickness, LVPWT); (3) LVFS percentage, using the following formula: LVFS = (LVEDD -LVESD) / LVEDD 3 100; (4) LVEF, using the following formula: LVEF = (LV end diastolic area -LV end systolic area) / LV end diastolic area 3 100; (5) maximal early diastolic flow velocity (E wave); (6) maximal late diastolic flow velocity (A wave); and (7) the ratio between E and A curves (E/A, normal value .1). The LVM was calculated by using Devereux's formula according to Penn's convention with the regression-corrected cube formula, LVM = 1.04
3 ] -13.8 g, and expressed by LVM index after correction for body surface area.
Similarly, to assess RV function and structure, we evaluated the tricuspid annular plane systolic excursion (TAPSE) detected by apical four-chamber view placing the M-mode marker perpendicular to the tricuspid annular plane and measuring the distance from the base to apex of the M-mode curve obtained, RV end diastolic diameter by apical four-chamber view, and RV fractional area change obtained by the following formula: RV fractional area change = (RV end diastolic area -RV end systolic area) / RV end diastolic area 3 100. Measurements were evaluated in all patients and controls at baseline and after 1 year of follow-up.
Cardiopulmonary exercise testing
Both patients and controls underwent an incremental cardiopulmonary exercise test on a bicycle ergometer (Ergoline Ergometrics 800; Bitz, Germany). Before each test, oxygen and carbon dioxide analyzers and a flow mass sensor were calibrated by the use of available precision gas mixtures and a 3-L syringe, respectively. All equipment was calibrated according to the instructions of the manufacturer before testing. To stabilize gas measurements, patients were asked to remain still on the ergometer for at least 3 minutes before starting exercise. After a 1-minute warm-up period at 0 workload, a ramp protocol of 15 W/min was started and continued until exhaustion. The pedaling was kept constant at 55 to 65 revolutions per minute. All patients were verbally encouraged to exercise to exhaustion, as assessed using a cutoff .1.1 for the respiratory exchange ratio at peak exercise. After maximal exercise has been reached, a cooling-down phase consisted of 5 minutes of pedaling at a slow rate (,40 revolutions/min) at a work rate of 0 W. A 12-lead electrocardiogram was monitored continuously during the test, and cuff BP was manually recorded every 2 minutes. Respiratory gas exchange measurements were obtained breath by breath with the use of a computerized metabolic cart (Vmax 29C; Sensormedics, Yorba Linda, CA). Peak oxygen consumption (VO 2 peak) was recorded as the mean value of VO 2 during the last 20 seconds of the test and was expressed in milliliters per kilogram per minute. At the end of the cardiopulmonary exercise test, patients were asked to identify the primary reason for stopping. Medical treatment administered the day of exercise testing was recorded. VO 2 peak was also expressed as the percentage of the maximal predicted VO 2 (peakVO 2 %) automatically computed by use of a protocolspecific formula adjusted for sex, age, height, and weight outlined by Wasserman et al. (19) . O 2 pulse (mL/beat) was automatically computed by dividing VO 2 by HR obtained every 10 seconds during cardiopulmonary exercise stress testing. The ventilatory anaerobic threshold was detected by two experienced reviewers (C. V. and F. G.) by use of the V-slope method (20) .
Statistical analysis
Statistical analysis was performed using SPSS (SPSS Statistics for Windows, Version 20.0, IBM Corp., Armonk, NY). Data are presented as mean 6 standard deviation. Differences between patients and controls at baseline and at the end of the study were assessed using t test for unpaired samples; differences in GHD patients before and after 1 year of GH therapy and differences in controls before and after 1 year of follow-up were evaluated through t test for paired samples. An additional evaluation between groups was performed for cardiopulmonary variables, using a linear regression model after adjustment for LBM.
Covariates found significantly different between the two groups were then analyzed by a stepwise multiple regression analysis to investigate the effects of several independent factors on cardiopulmonary functional capacity and cardiac performance endpoints in GHD patients. Statistical significance was set at 5%.
Results
Anthropometric measurements and IGF-1
As expected, at study entry patients were significantly shorter than controls (P = 0.0001); height improved significantly after 1 year of treatment with GH (P = 0.006), but was still significantly lower than controls after 1 year of treatment (P = 0.001; (Table 1) . WHtR (0.48 6 0.05 vs 0.44 6 0.05, P = 0.013) was higher at baseline in GHD patients compared with controls, but significantly reduced (0.45 6 0.04, P = 0.04) after 1 year of GH therapy, becoming similar to the control group (Table 1) .
Systolic BP, diastolic BP, and HR were comparable between patients and controls and did not change in GHD subjects during therapy (Table 1) . At baseline, as expected, IGF-1 SDS was significantly reduced in patients as compared with controls (P = 0.005) and significantly increased after 1 year of GH treatment (P = 0.0001; Table 1 ), similar to controls at the end of the study.
Body composition
At study entry, LBM (22,011 6 4998 vs 27,275 6 5078 g, P = 0.006) and LBM (65.36 6 7.84% vs 76.13 6 8.23%, P , 0.0001) were significantly lower, whereas FM (11,407 6 5933 vs 8066 6 2979 g, P = 0.014) and FM (30.84 6 7.92% vs 22.19 6 8.18%, P = 0.001) were significantly higher in GHD patients compared with controls (Table 1) . After 1 year of GH treatment, an improvement in body composition was observed in GHD patients with a significant increase in LBM (33,629 6 10,863 g, P , 0.0001) and LBM (75.36 6 7.59%, P = 0.0001), a significant reduction in FM (22.62 6 7.73%, P = 0.001), and a trend toward reduction in FM (9589 6 4151 g; Table 1 ).
PA assessment
According to the International Physical Activity Questionnaire categorical scoring system, 17 of 21 (81%) patients and 17 of 21 (81%) controls had a low intensity level Abbreviations: NA, not available; NS, not significant; P a , GHD vs controls at baseline; P b , GHD after 1 year of GH vs controls after 1-year follow-up; P c , GHD at baseline vs 1 year of GH and controls at baseline vs controls after 1-year follow-up.
of PA, and four of 21 (19%) in both patients and controls had a moderate intensity level of PA.
Echocardiography
Results of echocardiography are summarized in Table 2 . At study entry GHD patients presented significantly lower LV size than controls (LVEDD P = 0.001; LVESD P , 0.05; IVST P = 0.02; LVPWT P = 0.01), resulting in a reduced LVM (P = 0.006).
LVFS and LVEF were only slightly, but not significantly, reduced in GHD patients than in controls. The E/A ratio was comparable between the two groups.
In GHD patients, 1-year GH replacement therapy significantly improved LVESD (P , 0.05), IVST (P = 0.006), LVPWT (P = 0.01), and LVM (P = 0.03), which all became comparable to healthy subjects (Table 2) ; LVEDD also significantly improved after treatment (P , 0.02), although at the end of the study, it was still slightly lower in GHD patients (P = 0.01; Table 2 ). No significant changes in LVFS, LVEF, and E/A ratio were observed.
At study entry, no differences were found in RV diameter, RV fractional area change and TAPSE between GHD patients and controls. Moreover, these parameters did not significantly change during GH treatment.
Cardiopulmonary exercise testing
At baseline, GHD children, compared with controls, showed significantly lower values of VO 2 peak (22.92 6 4.80 vs 27.48 6 6.71 mL/Kg/min, P = 0.01), VO 2 peak% (45.19 6 10.02 vs 54.48 6 12.18%, P = 0.02), peak workload (80.62 6 29.32 vs 103.76 6 36.20 W, P = 0.02) and O 2 pulse (4.93 6 1.30 vs 7.67 6 2.93 mL/beat, P = 0.0003; Table 3 , Fig. 1 ). After correction for LBM, differences in VO 2 peak, VO 2 peak%, and O 2 pulse still remained significant (P = 0.04, P = 0.01, and P = 0.001, Abbreviations: NA, not available; NS, not significant; P a , GHD vs controls at baseline; P b , GHD after 1 year of GH vs controls after 1-year follow-up; P c , GHD at baseline vs 1 year of GH and controls at baseline vs controls after 1-year follow-up; RVFAC, RV fractional area change; RVEDD, right ventricular end diastolic diameter.
respectively), whereas peak workload became comparable between the two groups (Table 3) . GH therapy resulted in a significant improvement in all cardiopulmonary functional capacity parameters, which became comparable to those obtained in the control group (Table 3, Fig. 1 ). Anaerobic threshold was identified in 12 out of 21 patients at baseline and in only 2/21 after 1 year of GH treatment. HR (174.14 6 16.87 vs 169.58 6 14.45 bpm), systolic BP (127.48 6 18.62 vs 130.24 6 18.27 mm Hg), and diastolic BP (75.71 6 10.74 vs 75.62 6 9.88 mm Hg) recorded at maximal exercise were similar between patients and controls at study entry, and did not change after 1 year of GH treatment. Multiple regression analysis showed that changes in peak workload were significantly correlated to changes in IGF-1 (b = 0.59, P = 0.004) and LBM (b = 0.45, P = 0.04).
Discussion
The results of this observational, case-control, prospective study indicate that (1) children with untreated GHD have reduced LVM, impaired body composition, and cardiopulmonary functional capacity compared with healthy controls, and (2) short-term GH replacement therapy exerts beneficial effects on cardiac structure, body composition, and cardiopulmonary functional capacity.
This study investigated the effects of GHD and GH replacement therapy on cardiopulmonary functional capacity in a pediatric cohort. Although not having apparent limitations in their daily PA, our data indicate that GHD children may have limitation of exercise capacity. In particular, compared with healthy controls, patients with GHD exhibited significantly lower baseline VO 2 peak, which is considered the gold standard measure of aerobic functional capacity, and reduced peak workload and oxygen pulse, which represents a noninvasive estimate of stroke volume and of cardiac output (21) . A 1-year course of GH treatment significantly improved all these measures of aerobic exercise performance, which became comparable to healthy controls. These results are particularly interesting because a better cardiopulmonary performance in childhood is associated to long-term beneficial effects such as reduced CV risk and improved bone mineral density and psychological well-being (22, 23) .
Our results are consistent with those reported in GHD adults. In fact, despite a few contrasting results (24) , there is a general agreement that GHD adults have poor exercise tolerance and suboptimal maximum oxygen uptake (25, 26) . Several placebo-controlled studies have documented a relevant increase in exercise capacity and maximum oxygen uptake after 6-12 mo of GH replacement therapy (27) (28) (29) (30) . Furthermore, in a double-blind placebo-controlled study, GH restart in 20 childhoodonset GHD patients, off treatment of at least 2 years, was associated with a significant improvement of exercise capacity (31) .
Favorable short-term effects of GH treatment on maximum power output and VO 2 peak have been also confirmed by two recent meta-analysis including 268 patients from 11 studies (3) and 306 patients from 15 studies (4), respectively. In both meta-analyses, removal of studies with a predominance of childhood-onset GHD patients did not alter the significance of the results, thus suggesting that the effects of GHD and GH replacement therapy on physical performance are independent of the duration of GHD and/or GH replacement therapy (3, 4) . In addition, no correlation was found between the Abbreviations: NS, not significant; P a , GHD vs controls at baseline; P b , GHD vs controls at baseline after correction for LBM; P c , GHD after 1 year of GH vs controls after 1 year follow-up; P d , GHD at baseline vs 1 year of GH and controls at baseline vs controls after 1-year follow-up; RVFAC, RV fractional area change; RVEDD, right ventricular end diastolic diameter.
improvement in exercise capacity variables, GH dose, initial IGF-1 concentrations, or age at diagnosis (3). Several lines of evidence in adult GHD suggest that decreased VO 2 peak may be proportional to the reduction in skeletal muscle mass (32) and that improvement in physical performance in response to GH may reflect the parallel increase in LBM and muscle volume (27, 32) . Indeed, the amount of skeletal muscle mass plays a key role in the regulation of metabolic changes and oxygen uptake during exercise (33) (34) (35) . Other abnormalities in body composition, such as increased amount of FM, which represents a mechanical limitation; disproportionate body fat distribution; and reduced extracellular water may further impair the ability to exercise (3) .
Data on body composition in children and adolescents with GHD are scanty (6, 36, 37) but point toward a relevant effect of GH deficiency and GH replacement. Accordingly, our data confirm that GHD is associated with lower LBM and higher FM in comparison with healthy controls, whereas GH therapy induces beneficial effects on these parameters. Although it could be hypothesized a relationship between changes in body composition and aerobic exercise performance, regression analysis documented that in our children, GH-induced changes in LBM correlated to changes in peak workload, but not to changes in VO 2 peak or O 2 pulse. In keeping with this, after adjustment for differences in LBM, VO 2 peak, and O 2 pulse remained significantly lower in untreated GHD children suggesting that, in addition to alterations in body composition, other GH-related factors also influence cardiopulmonary capacity. However, the small sample size of our study and the lack of data on muscle volume and strength and on body fat distribution limit the ability to find significant correlations between changes in body composition and improvement in aerobic capacity measures. Furthermore, a major limitation of our study is that DXA was not repeated in controls after 1 year of follow-up thus not allowing the evaluation of physiological effects of growth, age or puberty on changes in body composition. Noteworthy, it is well known that GH has pleiotropic effects and an intricate combination of other factors may also account for the improvement of aerobic capacity observed after starting GH treatment, such as increased availability of energy substrate (i.e., free fatty acids and glycerol levels, reflecting its lipolytic effects), more efficient hematopoiesis, cardiac contractility, and thermogenesis (5, 38, 39) . In this respect, we found, in agreement with our previous studies (12, 13) , that GHD children have reduced LVM, which significantly improves upon starting GH treatment. Therefore, it could be hypothesized that favorable changes in ventricular size may play an important role in improving aerobic capacity in GHD patients. Echocardiographic study in our patients also included the assessment of RV structure and function, which did not appear to be affected by GHD. There is no information available about RV modification by GHD; our results suggest that RV function and development are not influenced by GH. However, these data cannot be considered conclusive and, because echocardiography is not the gold standard for RV structure and function evaluation, further studies with other techniques such as cardiac magnetic resonance may clarify the role of GH in RV remodeling and function.
In conclusion, children with GHD have reduced LVM, impaired body composition, and cardiopulmonary functional capacity compared with healthy controls. Short-term GH replacement exerts beneficial effects on cardiac structure, body composition, and cardiopulmonary functional capacity. Cardiopulmonary exercise stress testing could be considered in the baseline evaluation of untreated GHD patients to unmask mild alterations of aerobic capacity.
These results further support the evidence that GHD in children may be associated to a cluster of CV risk factors. Studies in larger populations are needed to confirm our findings and to further clarify the underlying mechanisms.
